Triaminic Cough & Sore Throat and Vyndamax
Determining the interaction of Triaminic Cough & Sore Throat and Vyndamax and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Based on in vitro data, coadministration with tafamidis may increase the plasma concentrations and the risk of toxicity of drugs that are substrates of the transport protein breast cancer resistance protein (BCRP) (e.g., methotrexate, rosuvastatin, imatinib), uridine diphosphate glucuronosyltransferase (UGT) 1A1 (e.g., bictegravir, irinotecan, raltegravir), and/or uptake transporters OAT1 and OAT3 (organic anion transporters) (e.g., bumetanide, furosemide, lamivudine, methotrexate, oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, zidovudine, zalcitabine) at clinically relevant concentrations. The proposed mechanism is decreased clearance due to tafamidis-mediated inhibition of the corresponding transport protein. MANAGEMENT: Caution is advised if tafamidis is used concomitantly with drugs that are substrates of these transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever tafamidis is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects. References Agencia Española de Medicamentos y Productos Sanitarios Healthcare "Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]): "Product Information. Vyndaqel (tafamidis)." Pfizer U.S. Pharmaceuticals Group, New York, NY. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Based on in vitro data, coadministration with tafamidis may increase the plasma concentrations and the risk of toxicity of drugs that are substrates of the transport protein breast cancer resistance protein (BCRP) (e.g., methotrexate, rosuvastatin, imatinib), uridine diphosphate glucuronosyltransferase (UGT) 1A1 (e.g., bictegravir, irinotecan, raltegravir), and/or uptake transporters OAT1 and OAT3 (organic anion transporters) (e.g., bumetanide, furosemide, lamivudine, methotrexate, oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, zidovudine, zalcitabine) at clinically relevant concentrations. The proposed mechanism is decreased clearance due to tafamidis-mediated inhibition of the corresponding transport protein.
MANAGEMENT: Caution is advised if tafamidis is used concomitantly with drugs that are substrates of these transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever tafamidis is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.
- Agencia Española de Medicamentos y Productos Sanitarios Healthcare "Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):
- "Product Information. Vyndaqel (tafamidis)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: acetaminophen / dextromethorphan
Brand name: Children's Triacting, Triaminic Cough & Sore Throat, Triaminic Cough & Sore Throat Softchews, Tylenol Childrens Plus Cough & Sore Throat, Tylenol Cough, Drixoral Cough/Sore Throat, Tylenol Cough and Sore Throat Daytime, Children's Tylenol Cold + Cough + Sore Throat, Children's Triaminic Cough and Sore Throat, Childrenâs Tylenol Plus, Triaminic Cough/Sore Throat, Tylenol Cough/Sore Throat
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Triaminic Cough & Sore Throat-Vyndaqel
- Triaminic Cough & Sore Throat-Vytone
- Triaminic Cough & Sore Throat-Vytone Cream
- Triaminic Cough & Sore Throat-Vytorin
- Triaminic Cough & Sore Throat-Vyvanse
- Triaminic Cough & Sore Throat-Vyvanse (Lisdexamfetamine Capsules)
- Vyndamax-Triaminic Cough & Sore Throat (pseudoephedrine)
- Vyndamax-Triaminic Cough & Sore Throat Softchews
- Vyndamax-Triaminic Day Time Cold & Cough
- Vyndamax-Triaminic Day Time Night Time Cold & Cough
- Vyndamax-Triaminic Decongestant
- Vyndamax-Triaminic Decongestant/Cough Infant